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E-mail: spluz@cbm.csic.esHerpes simplex virus 1 (HSV-1)-derived amplicon vectors are
unique in their ability to accommodate large DNA molecules
allowing whole genomic loci to be included with all of their reg-
ulatory elements. Additional advantages of these amplicons
include their minimal toxicity and ability to persist as epi-
somes, with negligible risk of insertional mutagenesis, being
particularly well-suited for gene therapy of neurological disor-
ders due to their outstanding ability to deliver genes into neu-
rons and other neural cells. However, extensive gene therapy
application has been hindered by difficulties in vector produc-
tion. This work improved HSV-1 amplicons production by ge-
netic modification of the packaging cell line and optimization
of the culture medium. A stably-transfected Vero 2-2 cell line
overexpressing the anti-apoptotic Bcl-2 protein was generated,
exhibiting an increased resistance to apoptosis, prolonged cul-
ture duration, and a significant improvement in viral vector
production. Additionally, supplementation of the growth me-
dium with antioxidants, polyamines, amino acids, and reduced
glutathione further increased the yield of packaged amplicon
vectors. With these modifications, HSV-1 amplicons could be
isolated from culture supernatants instead of cell lysates, lead-
ing to vector preparations with higher titer and purity and
paving the way for generation of stable cell lines that are
capable of continuous herpesviral vector production.
INTRODUCTION
Many efforts have been made to improve gene therapy of genetic dis-
orders.1,2 An ideal gene therapy protocol consists of single-adminis-
tration of the therapeutic gene, which subsequently persists and seg-
regates alongside chromosomes, maintained in episomes to avoid risk
of insertional mutagenesis.3,4 One of the main challenges from the
beginning of gene therapy research was targeting genes of interest
to specific cells, tissues, or organs, which was resolved using the nat-
ural ability of viruses to infect cells.5,6 Viruses are appropriate tools for
gene therapy because of their high efficiency in infecting cells, and
different viral vector systems have been developed as vehicles to
deliver DNA “in vitro,”7 including adenovirus, retrovirus (lentivirus),
and adeno-associated viruses. Each system has inherent advantages
and disadvantages related to their own viral characteristics, but they
all share one common inconvenience: the amount of packaged exog-Molecular Therapy: Methods &
This is an open access article under the CC BY-NC-enous DNA is limited to the viral genome size. To overcome this hur-
dle, most constructs used for gene therapy are based on cDNAs
controlled by heterologous promoters, though their improper regula-
tion may cause variable expression or even complete silencing,8
restricting their usefulness.
Alternatively, inclusion of entire genomic loci provides all necessary
regulatory elements to ensure controlled, physiological expression
of the transgene,9 already shown for mice transgenesis technol-
ogy.10,11 Use of large fragments of genomic DNA permits delivery
of intact mammalian genes with all introns, promoters, enhancers,
and long-range controlling elements, providing near-endogenous
levels of expression12 and tissue specificity.13 In order to accommo-
date such large DNA fragments (up to 150 kb) in a viral vector, viruses
with larger genomes must be used, such as herpes simplex virus 1
(HSV-1). Other features that make HSV-1 suitable as a delivery
particle are its broad cell tropism and the fact that its genome doesn’t
integrate into the host cell chromosomes.14 One strategy for the use
of HSV-1 in gene delivery is through amplicon vectors, which are
plasmids or bacterial artificial chromosomes (BACs) that contain
only two sequences of viral origin: the oriS element, which allows
replication in packaging cells, and a pac sequence for packaging
into HSV-1 viral particles.15–17 Amplicons are packaged into viral
particles using a “helper virus-free” packaging system (from transient
cotransfection with an oversized helper HSV-1 genome lacking
pac and ICP27 sequences),18 which reduces the possibility of cyto-
pathic effects.
The strategies used to make viral-based vectors safer vehicles for
gene therapy are directly associated with lower virus production,19
which complicates translation of this technology into the clinical
setting. As interest in the use of viral particles in gene therapy in-
creases, so do efforts to achieve higher titers and purity of theClinical Development Vol. 17 June 2020 ª 2020 The Authors. 491
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Characterization of the New Packaging Cell
Line, 2-2 Bcl2
(A) Western blot analysis of cell culture extracts. SDS-PAGE
was performed using cell lysates from parental Vero 2-2
(2-2) and novel Vero 2-2 cells constitutively expressing the
anti-apoptotic Bcl-2 protein (2-2 Bcl2). Bcl-2, pro-caspase-
3, and caspase-3 were detected in western blots by spe-
cific antibodies. (B) Cell death during generation of HSV-1
vectors at 1, 3, and 6 days. Scale, 10 mm. (C) Maximum
infectious titer of HSV-1-based amplicon vectors in 2-2
Bcl2 cells. After production of amplicon vectors in parental
Vero 2-2 (2-2) and novel 2-2 Bcl2 cells, infectious titers
(IU/mL) were determined in G 16-9 cells. Vertical axis rep-
resents infectious titer relative to that produced in Vero 2-2
cells; values presented are mean ± SEM; n = 3. Student’s
t test was used to compare amplicon vector generation in
both cell lines (***p < 0.001).
Molecular Therapy: Methods & Clinical Developmentin vitro preparations and in consequence the production of most
viral particles (adenovirus, adeno-associated, and lentivirus-
derived vectors) has undergone a considerable improvement over
time.20 In the case of HSV-1 amplicon vectors, however, such im-
provements in their production has been more limited, especially
for helper-free herpesviral amplicon vectors bearing large DNA
constructs.21,22
The higher nutritional demands required of virus-producing cell
lines forces myriad physiological changes during viral packaging.
Indeed, a recent report identified several metabolic pathways
such as polyamine and glutathione biosynthesis as limiting the
production of recombinant enveloped viruses.23 Multiflux analysis
has revealed that several metabolic pathways are altered when
comparing virus production with normal cell growth, and metab-
olite supplementation in growth media can result in huge improve-
ments in titer.24,25
At the same time, introduction of foreign DNA into packaging cell
lines via lipofection induces the apoptotic cascade,26 leading to
increased cell mortality and lower titers of the viral suspension.
Apoptosis is a natural cellular process regulated by different factors,
including Bcl-2, an anti-apoptotic protein.27 Overexpression of
anti-apoptotic proteins has been used to prolong viability of cell cul-
tures, enhancing industrial production of recombinant proteins.28
Interestingly, overexpression of Bcl-2 has additional metabolic effects
that may be useful to enhance viral production in mammalian cell
cultures.29492 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020In this study, the efficiency of production of
HSV-1 amplicon vectors was enhanced using a
novel packaging cell line stably expressing Bcl-2
and optimization of growth medium by adding
different nutritional supplements such as antiox-
idants, polyamines, reduced glutathione, and an
amino acid mixture, already shown to increase vi-
rus production.23 Both strategies helped to avoidcytotoxicity and massive cell death during the packaging process,
leading to enhanced production of vectors in vitro.
RESULTS
The Novel Packaging Cell Line 2-2 Bcl2 Shows Apoptosis
Resistance and Increased Production of HSV-1 Amplicon
Vectors
During the packaging process, massive cell death is triggered by pro-
duction of viral particles and transfection of exogenous DNA.26
Generating HSV-1 amplicon vectors at high titers is difficult when
transfecting BAC-sized DNA, so it was imperative to optimize proto-
cols. A novel packaging cell line, 2-2 Bcl2 (stably expressing the anti-
apoptotic Bcl-2 protein), was generated and found to express higher
levels of pro-caspase-3 and lower levels of active caspase-3 (Fig-
ure 1A), which would suggest that the new cell line has a resistance
to the apoptotic process. Indeed, this was confirmed by propidium io-
dide assays highlighting lower levels of cell death in 2-2 Bcl2 cells
compared to the original Vero 2-2 cells (Figure 1B). A boost in
HSV-1 vector production was also observed in 2-2 Bcl2 cells, with a
40% increase (2.88 105 versus 3.9 105 infective units per milliliter
(IU)/mL) in generation of viral particles with respect to the parental
cell line (Figure 1C). Thus, the new, genetically modified cell line is a
suitably improved platform to generate HSV-1 amplicon vectors.
Supplementation of Packaging Cell Growth Medium Increases
Yield of HSV-1 Amplicon Vectors
In order to offset the increased nutritional demands of viral produc-
tion, cell growth media was supplemented with amino acids,
Figure 2. Optimization of the Packaging Cell Growth
Medium
Quantification of vector production in Vero 2-2 cells ex-
pressing Bcl2 grown in standard medium (control) or sup-
plemented alone or in combination with amino acids (aas),
antioxidants (antiox), polyamines (polya), and reduced gluta-
thione (r.gluta), or containing all the supplements (complete).
Values are presented as mean ± SEM; n = 3. Student’s t test
was used to compare amplicon vector generation in the
different media (***p < 0.001; **p < 0.01; *p < 0.05).
www.moleculartherapy.organtioxidants, polyamines, and reduced glutathione, targeting those
pathways more affected during viral vector generation.23 The supple-
ments were added to the media alone or in combination after trans-
fection of exogenous DNA for packaging, and supernatants were
collected after 3 days. Separately, each showed a tendency to increase
the efficiency of viral vector production, although only amino acid
supplementation gave a statistically significant result (Figure 2).
Addition of polyamines or antioxidants yielded a 1.2-fold improve-
ment in viral titer, whereas reduced glutathione had a 1.3-fold in-
crease. When multiple supplements were combined, there was
a 1.8-fold increase, and use of all four supplements resulted in
2.3-fold enhancement (8.06  104 versus 1.97  105 IU/mL) with
respect to the non-supplemented medium (Figure 2).
Current packaging protocols are limited to 3 days18 after which
yield drops dramatically. Once the optimal medium was estab-
lished, the maximum duration of packaging was determined in
the 2-2 Bcl2 cells. As decreases in viral yield may be due to inac-
tivation of particles by accumulation of cellular waste, culture
media was replaced every 48 h, and amplicon vectors were har-
vested from the supernatant. Neither the new cell line nor the en-
riched growth medium was successful in lengthening the period of
virus production, probably suggesting that low yield of virus
production after 3 days is due to the transient transfection (data
not shown).
2-2 Bcl2 Cells Enhance Yield of Large Plasmid Packaging
All previous packaging experiments to check the efficiency of the new
Bcl-2-expressing cell line and medium supplementation were carried
out with the 8 kb plasmid pHSV-lac. However, as one of the most
interesting features of HSV-1 vectors is their large packaging capacity,
able to harbor exogenous DNA up to 150 kb, the yield of packaging a
140 kb BAC containing a whole genomic locus was tested using the
updated protocols. Use of the optimized media in parental 2-2Molecular Therapy: MethodsVero cells resulted in a 3-fold increase in pack-
aging process, whereas the new 2-2 Bcl2 cells
cultured in standard and optimized growth me-
dium had a 4-fold (7.83  103 versus 3.03 
104 IU/mL) and 4.7-fold increase (7.83  103
versus 3.72  104 IU/mL) in virus production,
respectively (Figure 3). Curiously, the effect of
medium supplementation was greater in parentalVero 2-2 cells than the 2-2 Bcl2 cells, perhaps due to metabolic
changes triggered by Bcl-2 overexpression.
DISCUSSION
Gene therapy research has made remarkable strides over the last 30
years, with some success treating cancer, metabolic disorders, and
several neurological diseases.30,31 A number of new vector systems
have been developed with broad potential; however, commercializa-
tion of gene therapy is in its infancy, and different issues must be
resolved before it joins standard medical practice.1 Viral vectors are
the most suitable for use in gene therapy, proven by the fact that
nearly two-thirds of gene therapy clinical trials are being performed
with them (http://www.abedia.com/wiley). Retrovirus and lenti-
virus-based approaches are by far the most popular, as these vectors
integrate into the host genome and provide lifelong expression of the
therapeutic gene. Yet, this can become disadvantageous due to asso-
ciated insertional mutagenesis events.32 The main way to avoid this
problem is the use of a non-integrating virus, such as HSV-1, which
also has the advantage of a large storage capacity. The ability to pack-
age complete genomic loci with all regulatory sequences13 or to pro-
duce different gene products9 in general allows a more physiological
expression of the therapeutic gene. Herpesviral vectors are therefore
considered to have great potential for gene therapy and other applica-
tions,33 but major hurdles remain for optimization of production.
Working with HSV-1-based vectors is quite cumbersome, as they are
mainly generated using BACs containing genomic loci to benefit from
their “storage” capacity. During the packaging process, the therapeu-
tic gene-containing BACs, as well as a BAC containing the viral genes
needed to form viral particles, are lipofected into a special cell line. As
transfection of BACs is not as efficient as for small plasmids, and
because the process triggers apoptosis, production yields low viral ti-
ters. In order for HSV-1 vectors to become true alternatives for ther-
apeutic use, it is necessary to achieve higher titers and purity.& Clinical Development Vol. 17 June 2020 493
Figure 3. Comparison of Large-Plasmid Packaging Efficiency in Cell Lines,
with and without Optimized Cell Culture Media
Packaging of a 140 kb BAC (pEHHG-FXN) was compared in parental Vero 2-2 (2-2)
and novel 2-2 Bcl2 cells grown in standard (control) or supplemented growth media
(nutrients). Vertical axis represents vector production relative to that of control cells
grown in standard, unsupplemented growth media; values are means ± SEM; n = 4.
Student’s t test was used to compare amplicon vector generation (**p < 0.01;
*p < 0.05).
Molecular Therapy: Methods & Clinical DevelopmentIn this work, viral particles were obtained without breaking cells in or-
der to prevent generation of cellular debris and to get higher purity
preparations, which will be essential for future clinical trials. How-
ever, as viral particles are mainly concentrated within cells, it is neces-
sary to seek solutions to increase the titer in the supernatant. Bearing
in mind that different factors play a role in cellular death, various ap-
proaches were used to address the problem. First, programmed cell
death was reduced in a new packaging cell line expressing anti-
apoptotic Bcl-2 protein, with a clear effect of increasing the produc-
tion of HSV-1 vectors. A previous study reported that overexpression
of Bcl-2 in HEK293 cells resulted in improved cell resistance to
apoptosis and prolonged culture duration but reduced production
of adenoviruses.34 The different outcome observed in this study
may be due to the different virus assembly machinery of adenovirus
and herpesvirus or the distinct cell lines tested.
Unfortunately, viral production dropped dramatically after 3 days of
culture in Bcl-2 overexpressing cells, probably due to the transient
nature of transfection. The fact that Bcl-2 expression protects pack-
aging cells from apoptosis may be used to attempt stable transfection
of with the packaging construct, since it is known that packaging
BACs is cytotoxic by itself.
Animal cell culture is a powerful tool for production of biologically
important molecules such as monoclonal antibodies, vaccines, and
recombinant proteins, though protocols must be optimized to maxi-
mize production. Metabolic studies have indeed concluded that
addition of different nutrients to the culture medium is a rapid
and effective way to improve these products.25,35,36 Specific nutri-494 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2tional requirements vary by cell line, but supplementation with amino
acids, polyamines, reduced glutathione, and antioxidants has been
shown to be effective regardless of the cell type or production process.
Several studies have shown how viral production imposes stress on
packaging cells, and expression profile studies have demonstrated a
higher demand on diverse pathways of cellular metabolism in pack-
aging cells with respect to their parental cell lines.23 Taking this
into consideration, the growth medium of the packaging cells was
supplemented with different nutrients that may be limiting during
viral production. In our experimental model, addition of amino acids
alone produced a significant increase in viral production, possibly
indicating that this pathway is more affected during viral packaging.
However, as each of the supplements produced a visible increase in
virus production, the results clearly suggest scarcity of all of them,
and indeed the effect was strongest when all the supplements were
included together in the packaging medium.
In conclusion, our study improved HSV-1 virus production by ge-
netic modification of the packaging cell line and supplementation
of the culture medium. These changes allow HSV-1 amplicons to
be isolated from culture supernatants instead of cell lysates leading
to purer viral preparations, a good starting point for production of
therapeutic herpesviral products with higher titers. With additional
studies to improve the packaging process, the use of herpesviral vec-
tors in gene therapy may become feasible for the treatment of human
diseases in the near future.
MATERIALS AND METHODS
Cell Culture
Parental Vero 2-2 cells and the novel Vero 2-2 cells stably expressing
Bcl2 (2-2 Bcl2) were routinely grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (Sigma, Madrid, Spain), 2 mM L-glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin in a humidified
incubator at 37C in 5% CO2.
The G16-9 cell line is derived from the human Gli-36 glioma cell line
and expresses the HSV-1 VP16 protein to enhance activity of the
pIE4/5-LacZ promoter cassette. G16-9 cells were cultured in
DMEM supplemented with 10% FBS, hygromycin-B (200 mg/mL),
100 U/mL penicillin, and 100 mg/mL streptomycin.
For generation of the 2-2 Bcl2 cell line, Vero 2-2 cells were transfected
using Lipofectamine and PLUS reagent (Thermo Fisher Scientific,
Waltham, MA, USA) with a plasmid containing the gene, a kind
gift from Belén Sanz-Castillo, and cells incorporating the plasmid
were selected in medium supplemented with puromicin (1 mg/mL).
Specific supplementation of growth medium was as described previ-
ously.23 Briefly, DMEM with 10% FBS and 2 mM L-glutamine was
supplemented with 1X antioxidants (Antioxidant Supplement
1000X, #A1345), 1X polyamines (Polyamine Supplement 1000X,
#P8483), 2 mM reduced glutathione (L-glutathione reduced,
#G6013), all from Merck Chemicals & Life Science S.A., Madrid,020
www.moleculartherapy.orgSpain; and an amino acid mixture prepared in the laboratory as
follows: serine (400 mM), asparagine (400 mM), arginine
(100 mM), methionine (100 mM), phenylalanine (100 mM), leucine
(300 mM), valine (300 mM), and isoleucine (300 mM).
Production and Titering of HSV-1 Amplicon Vectors
HSV-1 amplicon vectors were packaged using a helper virus-free
packaging system as described previously.18 Briefly, 3  106 of 2-2
and 2-2 Bcl2 cells were cotransfected in a 100 mm tissue culture plate
with 5.4 mg of amplicon DNA, 6 mg of fHSVDpacD27 0+, and 0.6 mg
of ICP27 using Lipofectamine and PLUS reagent (Thermo Fisher Sci-
entific). Plasmids pHSV-LacZ (8 kb) and pEHHG-FXN BAC
(140 kb)37 were used, each containing the elements required to be
packaged into herpesviral particles. After 72 h, HSV-1 amplicons
were concentrated by centrifuging viral preparations through a 25%
sucrose cushion at 100,000  g for 4 h at 4C, and the pellet was
re-suspended in Hank’s balanced salt solution (HBSS) (Life Technol-
ogies). Infectious titers (IU/mL) were determined on confluent G16-9
cell monolayers by X-gal staining for pHSV-LacZ or GFP expression
using a Axioskop2 fluorescence microscope (Carl Zeiss Microscopy,
Thornwood, NY, USA) for pEHHG-FXN BAC.
Western Blot Analysis
Protein production was analyzed in both cell lines, Vero 2-2 and the
new generated Vero 2-2 Bcl2. For protein extracts, cells were washed
once with PBS, placed on ice, and then homogenized in a buffer con-
taining 20 nM HEPES, pH 7.4, 100 mM NaCl, 100 mM sodium fluo-
ride, 1% Triton X-100, 1 mM sodium orthovanadate, 5 mM EDTA,
and the complete protease inhibitor cocktail (Roche, Barcelona,
Spain). After determination of the protein concentration using the
Bradford assay (Bio-Rad, Hercules, CA, USA), samples with equal
amounts of protein (10–15 mg) were combined with electrophoresis
buffer containing sodium dodecyl sulfate (SDS), boiled for 5 min,
and separated by electrophoresis in 10% and 15% acrylamide gels
in the presence of SDS. Proteins were transferred to nitrocellulose
membranes following standard procedures and blocked with 2%
FBS and 0.1% Tween-20 in PBS. Membranes were incubated over-
night at 4C with primary antibodies diluted in blocking solution,
then washed three times in PBS with 0.1% Tween-20, and finally incu-
bated with the corresponding secondary antibody for 2 h at room
temperature. After three further washes in PBS, immunofluorescent
proteins were visualized using the Odyssey System (LI-COR, Lincoln,
NE, USA). The monoclonal antiserum directed against Bcl-2
(1:1,000) was from Santa Cruz Biotechnology (Dallas, TX, USA).
The monoclonal antibody specific for b-tubulin (1:5,000) was from
Sigma, and the antibody against caspase-3 (1:1,000) was from Cell
Signaling Technology (Danvers, MA, USA). Secondary antibodies
(1:5,000) used for Odyssey were from LI-COR (Lincoln, NE, USA).
Cell Viability
Cell viability was assessed by calcein-propidium iodide uptake.38 Cal-
cein/acetoxymethyl ester is taken up and cleaved by esterases present
in living cells, yielding yellowish-green fluorescence. In contrast,
propidium iodide is taken up only by dead cells, which then exhibitMoleculorange-red fluorescence. Briefly, cells were incubated at 37C for
30 min with 8 mM propidium iodide (Merck) and 1 mM calcein/ace-
toxymethyl ester (Molecular Probes, Eugene, OR, USA). The cells
were stained at 1, 3, and 6 days, and visualized by a Axioskop2 fluo-
rescence microscope (Carl Zeiss Microscopy).
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